1. Home
  2. RYTM vs HWC Comparison

RYTM vs HWC Comparison

Compare RYTM & HWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$115.20

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Logo Hancock Whitney Corporation

HWC

Hancock Whitney Corporation

N/A

Current Price

$65.02

Market Cap

5.8B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
RYTM
HWC
Founded
2008
1883
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.8B
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
RYTM
HWC
Price
$115.20
$65.02
Analyst Decision
Strong Buy
Buy
Analyst Count
19
9
Target Price
★ $140.12
$83.69
AVG Volume (30 Days)
★ 1.5M
1.0M
Earning Date
11-03-2026
10-20-2026
Dividend Yield
N/A
★ 3.08%
EPS Growth
★ 28.34
7.39
EPS
N/A
★ 3.48
Revenue
N/A
N/A
Revenue This Year
$73.80
$6.40
Revenue Next Year
$73.86
$10.00
P/E Ratio
★ N/A
$18.63
Revenue Growth
N/A
N/A
52 Week Low
$74.50
$55.76
52 Week High
$122.20
$80.13

Technical Indicators

Market Signals
Indicator
RYTM
HWC
Relative Strength Index (RSI) 65.94 28.68
Support Level $82.31 $63.31
Resistance Level $119.75 $69.25
Average True Range (ATR) 6.84 1.79
MACD 2.19 -0.71
Stochastic Oscillator 94.00 14.06

Price Performance

Historical Comparison
RYTM
HWC

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About HWC Hancock Whitney Corporation

Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.

Share on Social Networks: